Instructions for use of venetoclax: detailed explanation of usage and dosage
Venetoclax/Venetoclax, as a highly effective oral drug, has been widely used to treat a variety of leukemias. Its tablets are available in three different strength options: 10 mg, 50 mg and 100 mg to ensure patients can make precise dosage adjustments based on their treatment needs. To ensure best results, it is recommended to take it at a fixed time each day with food and water.
Venetoclax has different medication regimens for different conditions. For people with chronic lymphocytic leukemia (CLL), the drug dose is gradually increased over a five-week cycle. For patients with acute myeloid leukemia (AML), the dose is escalated over four days and is usually combined with azacitidine, decitabine, or with a low dose of cytarabine on the first day.

Specifically,The medication regimen for CLL patients is as follows: 20 mg orally taken daily in the first week, then increased to 50 mg, 100 mg, and 200 mg each week. In the fifth week and beyond, the daily dose will be stable at 400 mg until the condition changes or the drug side effects reach an unacceptable level. This dose escalation strategy is designed to minimize the risk of tumor lysis syndrome (TLS).
ForAML patients, the medication regimen increases even more rapidly: 100 mg on the first day, 200 mg on the next day, and 400 mg on the third day. Beginning on day four, maintain a daily dose of 400 mg if coadministered with azacitidine or decitabine; or 600 mg if coadministered with low-dose cytarabine.
Venetoclax dosage is determined based on exhaustive studies that show a proportional increase in the drug's area under the steady-state curve (AUC) over the range of 150 to 800 mg. Of note, taking with food significantly increases drug exposure to venetoclax, which may increase by 3.4-fold with a low-fat diet and up to 5.3-fold with a high-fat diet.
During treatment, if toxicity-related adverse reactions occur, such as tumor lysis syndrome, Grade 3 neutropenia, or Grade 3/4 non-hematological toxicity, the drug dose may need to be adjusted accordingly.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)